Overview

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Status:
Terminated
Trial end date:
2018-09-06
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable background antidiabetic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Liminal BioSciences Ltd.
ProMetic Pharma SMT Limited